Subcutaneous ICD (S-ICD)

Details

The subcutaneous ICD (S-ICD; Boston Scientific EMBLEM) delivers defibrillation via a subcutaneous coil lead (no intracardiac leads) with sensing from three sensing vectors using two subcutaneous electrodes (parasternal and lateral chest wall). It does NOT deliver antitachycardia pacing (ATP) or chronic bradycardia pacing. Key advantages: avoids intravascular lead complications (infection, venous thrombosis, lead failure requiring extraction); suitable for patients with poor venous access, prior device infection, or young patients with long expected device lifetime. Disadvantage: inability to pace-terminate monomorphic VT or provide bradycardia support.

Key trials:

• PRAETORIAN (n=849, primary prevention LVEF ≤35% or SCD-risk condition): S-ICD noninferior to TV-ICD for device-related complications + inappropriate shocks at 4 years (15.1% vs 15.7%); no ATP capability did not translate to worse outcome
• UNTOUCHED (n=1,160, primary prevention LVEF ≤35%): inappropriate shock-free rate 95.9% at 18 months using optimal programming (SMART Pass + high-sensitivity zone + dual-zone); appropriate S-ICD shock 1.4/100 patient-years

SENSE algorithm and dual-zone programming substantially reduce inappropriate shocks — mandatory programming standard.

Key Facts

S-ICD Appropriateness — AUC 2025 Ratings

• Primary prevention, ischaemic or nonischaemic CM, LVEF ≤35%: A(7) — PRAETORIAN noninferior to TV-ICD (sources/icd-crt-auc-2025, rating: high)
• HCM primary prevention (≥1 SCD risk factor): A(7) (sources/icd-crt-auc-2025, rating: high)
• Congenital heart disease + venous obstruction or complex anatomy: A(8) — avoids transvenous lead complications (sources/icd-crt-auc-2025, rating: high)
• ESRD on haemodialysis (primary prevention): A(7) — avoids bacteraemia-related transvenous lead infection; PRAETORIAN-HD substudy data (sources/icd-crt-auc-2025, rating: high)
• Prior device infection requiring TV-ICD extraction with ongoing indication: A(8) — pivotal use case for S-ICD (sources/icd-crt-auc-2025, rating: high)
• Venous access obstruction (bilateral subclavian/SVC occlusion): A(8) (sources/icd-crt-auc-2025, rating: high)
• Secondary prevention after cardiac arrest (no ATP requirement, no pacing need): A(7) (sources/icd-crt-auc-2025, rating: high)

Scenarios Where S-ICD is Less Appropriate

• Documented sustained monomorphic VT (MMVT) requiring ATP: M(4–5) — S-ICD cannot terminate MMVT by pacing; TV-ICD preferred (sources/icd-crt-auc-2025, rating: high)
• ARVC primary prevention: M(5) — ARVC associated with VT often terminating by ATP; S-ICD less suitable (sources/icd-crt-auc-2025, rating: high)
• Requirement for bradycardia pacing support (SSS, AVB): Contraindication — S-ICD cannot pace chronically (sources/icd-crt-auc-2025, rating: high)
• CRT indication concurrent with ICD need: S-ICD cannot deliver biventricular pacing (sources/icd-crt-auc-2025, rating: high)

Screening Requirements

• Pre-implant surface ECG screening mandatory: Assess sensing vector eligibility in standing, sitting, and supine positions
• Approximately 5–10% of patients fail screening due to T-wave oversensing risk (common in LQTS, LVH with large T-waves, pectus deformity)
• QRS/T-wave ratio is key — must pass in ≥1 of 3 sensing vectors in all body positions

Inappropriate Shock Prevention

• Dual-zone programming: conditional zone (170–200 bpm) + shock zone (>200 bpm); SMART Pass filter for high-frequency T-wave oversensing (sources/icd-crt-auc-2025, rating: high)
• UNTOUCHED 95.9% inappropriate shock-free at 18 months with optimal programming (sources/icd-crt-auc-2025, rating: high)
• T-wave oversensing and R-wave double-counting remain the primary inappropriate shock mechanisms

Contradictions / Open Questions

• ARVC and S-ICD: ARVC VT is often monomorphic and may terminate with ATP — S-ICD's inability to ATP may result in prolonged VT or syncope before shock delivery. AUC rates M(5), yet some ARVC patients may be candidates if VT is rapid and VF-like. No head-to-head data in ARVC.
• Long-term device longevity: S-ICD battery longevity is 7–11 years vs 8–14 years for TV-ICD. In young patients (<40), multiple device replacements planned — each extraction carries risk. The subcutaneous coil lead has a different extraction profile than transvenous leads.
• Coexisting need for pacing (intermittent AVB): Hybrid systems (S-ICD + Micra leadless pacemaker) are emerging but interaction and cross-talk between devices not fully validated.
• PRAETORIAN generalisability: PRAETORIAN enrolled centres with SENSE algorithm and dual-zone programming expertise; real-world inappropriate shock rates may be higher without optimised programming.

Connections

• Related to entities/ICD — subcutaneous variant; same SCD prevention goal; differs in ATP capability
• Related to entities/Heart-Failure — primary prevention LVEF ≤35% A(7)
• Related to entities/HCM — A(7) for primary prevention
• Related to entities/ARVC — M(5); ATP need limits suitability
• Related to concepts/Sudden-Cardiac-Death — SCD prevention without intracardiac hardware
• Related to concepts/Conduction-Disorders-in-Young-Adults — young patients with long device lifetime benefit most

Sources

• sources/icd-crt-auc-2025 — ACC/AHA/HRS 2025 AUC (primary source; PRAETORIAN and UNTOUCHED data)